Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery
Information source: Nanjing Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Coronary Syndrome; Coronary Artery Disease
Intervention: Nicardipine , Esmolol (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Nanjing Medical University Official(s) and/or principal investigator(s): Shao-liang Chen, Director, Study Chair, Affiliation: Nanjing First Hospital,Nanjing Medical University
Overall contact: Shaoliang Chen, Director, Phone: +86-25-52208048, Email: chmengx@126.com
Summary
Both calcium channel antagonist and beta-blocker have cardioprotective effect. Endothelial
shear stress is predictive factor of clinical outcomes in patients with obstructive
stenosis.
The present study aims at comparing the re-distribution of shear stress and blood velocity
during whole cardiac cycle after trans-coronary injection of Nicardipine and esmolol.
Clinical Details
Official title: Nanjing First Hospital, Nanjing Medical University
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Endothelial shear stress assessed by computational fluid dynamics
Secondary outcome: Minimal lumen area by intravascular ultrasound
Detailed description:
Blood flow-induced endothelial shear stress has strong effect on endothelial function and
development or progression of plaque formation. It is extensively accepted that low and/or
oscillating shear stress causes endothelial dysfunction and is one of crucial factors in
localizing early atherosclerosis .In contrary, normal and high shear stress is atheroma
protective and is involved in compensatory remodeling . Most studies reported that the
endothelial shear stress distribution in often idealized geometrical models of human
coronary arteries was the subject of numerous investigations , and in these studies it was
shown that the geometry of coronary arteries is the main determinant of the observed shear
stress distribution. Generally, downstream of a plaque, low shear stress can be expected,
Several cardiovascular active drugs have been shown to be cardio-protective for patients
with obstructive coronary disease. Of these drugs, calcium channel blocker is one of most
prescribed in everyday clinical practice. Ninomiya et al. reported calcium channel blocker
was associated with increased coronary diameter and blood fluid with dose-dependent pattern
in patients with normal or mild stenotic coronary artery. However, no reports on the dynamic
change of endothelial shear stress after calcium channel blocker in - vitron were published
so far. As a result, the aim of this study was to evaluate the effect of intra-venous
injection of Nicardipine, one calcium channel blocker with shorter half-time, on the
re-distribution of endothelial shear stress in patients with acute coronary syndrome and
mild stenotic (<50%) coronary artery disease.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of unstable angina and non-Q wave myocardial infarction
- Age 18-75 yr.
- Diameter stenosis of coronary artery<70% diameter stenosis by visual estimation
- Blood pressure >110/70 mmHg
- Heart rate 60-~100 bpm, No cardiac arrhythmias
Exclusion Criteria:
- St-elevation myocardial infarction
- Lower blood pressure(<100/70mmHg)
- Heart rate <60 or >100 bpm, The presence of cardiac arrhythmias
- Allergy to study drugs
- Women in pregnancy
- Liver dysfunction
- Creatinine >2. 5mg/dl
- Bleeding stroke within 6 months
- Left ventricular ejection fraction<30% before maximal medication
Locations and Contacts
Shaoliang Chen, Director, Phone: +86-25-52208048, Email: chmengx@126.com
Nanjing First Hospital,Nanjing Medical University, Nanjing, Jiangsu 210006, China; Not yet recruiting Shao-liang Chen, Director, Phone: +86-25-52208048, Email: chmengx@126.com
Additional Information
Starting date: October 2010
Last updated: July 28, 2010
|